Stop TB Partnership

Part I - Strategic Directions

Achievements in 2000 - 2005 and Challenges for 2006 - 2015 [.pdf]
This section provides a brief description of the Partnership's structure and function, outlines the main achievements in global TB control since 2000, decribes the current TB situation today, and sets out the challenges that lie ahead.

Achieving the Targets: What Needs to be Done [.pdf]
In setting out the main strategic directions to achieve global targets for TB control, this section indicates the following:

  • the Partnership's vision, mission, and targets
  • the Partnership's strategic directions and objectives
  • the ways in which wider and wiser use may be made of existing strategies for TB control
  • strategies to address the challenges posed by emerging threats such as MDR-TB and HIV
  • the importance of operational research
  • the ways in which new TB diagnostic tests, drugs, and vaccines will be developed and adopted
  • the importance of technical cooperation in support of the implementation of effective TB control interventions
  • the main approaches to monitoring and evaluation

Key Cross-Cutting Issues: Strengthening Health Systems, TB and Poverty, TB in Children, and TB and Gender [.pdf]
As the Partnership's working groups take forward their individual strategic plans for 2006 - 2015, they will work within the overall holistic vision of the Global Plan to Stop TB. To do this, the Working Groups have to work together effectively and efficiently, and to take a common approach to key cross-cutting issues. This section addresses four such issues important to the Global Plan: health system strengthening, poverty, TB in children, and TB and gender.

Summary of Planned Achievements, Resource Needs and Impact [.pdf]
This section summarizes:

  • what would be achieved if the Plan is fully implemented
  • the resource needs to enable full implementation of the Plan
  • the expected impact of full implementation of the Plan on the TB epidemic

Conclusion

Implementation of the plan, at the cost of US$56 billion, will save some 14 million lives over the next 10 years, using only existing tools. But it will also be the precursor for future gains. Because TB dynamics are slow, implementation activities from 2006 to 2015 will yield benefits later as well as those shown here as occurring within the period of the Plan. Even more dramatically, the investment in new drugs, new diagnostic tests and new vaccines will begin to pay rich dividends beyond 2015. The real prize will be the elimination of TB.